<DOC>
	<DOCNO>NCT00950196</DOCNO>
	<brief_summary>Ataxia-Telangiectasia A-T neurodegenerative disorder cerebellum , manifest ataxia , well extrapyramidal feature . Treatment A-T discouraging , since treatment seem change course disease , improvement achieve symptomatic treatment bothersome movement disorder . While various dopaminergic agent occasionally use , report benefit rather sparse anecdotal . Amantadine , well know drug use influenza well movement disorder Parkinson , prove improve various type movement disorder ataxia , chorea , dystonia , akinesia attention span . The purpose study investigate weather amantadine sulphate improve ataxia movement disorder ( bradykinesia , parkinsonism , dystonia , chorea ) , well general well patient A-T .</brief_summary>
	<brief_title>Amantadine Improving Neurologic Symptoms Ataxia-Telangiectasia</brief_title>
	<detailed_description>Ataxia-Telangiectasia ( A-T ) complex multisystem disorder neurodegenerative course , immune deficiency , tendency develop malignancy .The clinical picture include progressive cerebellar ataxia along movement disorder ( chorea , dystonia bradykinesia ) may even disable ataxia . Fatigability , drool reduce stamina major concern . Disease course devastating : towards second decade life affect child usually bind wheelchair survival beyond second decade life rare . Treatment A-T discouraging , since treatment seem change course disease , improvement achieve symptomatic treatment bothersome movement disorder . While various dopaminergic agent occasionally use , report benefit rather sparse anecdotal . Amantadine dopaminergic agent approve prophylaxis influenza ( child 1 year age adult ) well extrapyramidal disorder adult : Parkinson disease drug induce dyskinesia . Amantadine increase dopaminergic transmission inhibit synaptic uptake , well antagonize striatal NMDA receptor ) . Additional condition find improved amantadine : cerebellar ataxia , vigilance brain trauma adult child , attention deficit disorder child , chorea akinesia Huntington 's disease . Amantadine FDA approve drug treatment prevention influenza , Parkinson disease drug induce dyskinesia ; approve use adult child 1 year age . Dosage child : 5 mg/kg body weight 8.8mg/kg/ . Dosage adult : 200 300 mg/day . The daily dosage divide 2 3 daily portion . Amantadine safe drug mild side effect : headache , decrease appetite , sedation , fatigue , abdominal pain , vomiting , insomnia , pedal edema rash ( 4-10 ) . Studies child prove amantadine safe tolerable drug . Amantadine administer 24 healthy child ADHD , age 5-13 year old . Side effect present 13/24 usually mild : decrease appetite , headache , sedation , mild insomnia , vomit , fatigue , abdominal pain . One subject drop headache . Six low response child traumatic brain injury treat amantadine ( concurrently medication ) The drug safe relatively mild side effect : sedation , intermittent tremor , dizziness , serious side effect require discontinuation protocol . Study purpose The purpose study investigate weather amantadine sulphate improve ataxia movement disorder ( bradykinesia , parkinsonism , dystonia , chorea ) , well general well patient A-T .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Ataxia Telangiectasia</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<criteria>diagnosis AT significant functional disability age 4 year major comorbidity : active malignancy require chemotherapy , kidney liver failure sexually active know hypersensitivity amantadine previous treatment amantadine 2 month precede study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>50 Months</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>